Manufacturer Requested Reimbursement Criteria1:
In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy.
|Call for patient/clinician input open||09-Nov-23|
|Call for patient/clinician input closed||08-Jan-24|
|Call for industry input open||09-Nov-23|
|Call for industry input closed||08-Jan-24|
Last Updated : November 10, 2023